FY2025 EPS Estimates for BeiGene Cut by Leerink Partnrs

BeiGene, Ltd. (NASDAQ:BGNE) – Investment analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of BeiGene in a report released on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn $0.73 per share for the year, down from their prior forecast of $0.79. The consensus estimate for BeiGene’s current full-year earnings is ($5.00) per share. Leerink Partnrs also issued estimates for BeiGene’s FY2026 earnings at $8.11 EPS and FY2027 earnings at $13.54 EPS.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.26 million. During the same quarter last year, the company posted $2.01 EPS. BeiGene’s revenue for the quarter was up 28.2% compared to the same quarter last year.

Other equities analysts have also issued reports about the stock. JMP Securities began coverage on shares of BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective for the company. JPMorgan Chase & Co. upped their price target on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a report on Tuesday, October 22nd. TD Cowen lifted their price objective on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday. StockNews.com upgraded shares of BeiGene from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Citigroup lifted their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.07.

BeiGene Trading Down 2.1 %

BeiGene stock opened at $189.23 on Thursday. The business’s fifty day simple moving average is $212.95 and its two-hundred day simple moving average is $181.80. The company has a current ratio of 1.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $18.43 billion, a price-to-earnings ratio of -22.96 and a beta of 0.63. BeiGene has a 12 month low of $126.97 and a 12 month high of $248.16.

Insider Activity

In other news, COO Xiaobin Wu sold 5,556 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total value of $26,021.78. The disclosure for this sale can be found here. Insiders sold 23,070 shares of company stock valued at $4,901,050 in the last quarter. 7.43% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BGNE. Blue Trust Inc. lifted its holdings in BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after purchasing an additional 75 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of BeiGene during the 3rd quarter valued at $36,000. Headlands Technologies LLC purchased a new position in shares of BeiGene during the 1st quarter valued at $50,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of BeiGene during the 3rd quarter valued at $67,000. Finally, SG Americas Securities LLC purchased a new position in shares of BeiGene in the third quarter valued at about $105,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.